A Randomised, Assessor- and Patient-blind, Multicentre, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Outcomes in Iron Deficient Non-anaemic Patients with Restless Legs Syndrome

Trial Profile

A Randomised, Assessor- and Patient-blind, Multicentre, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Outcomes in Iron Deficient Non-anaemic Patients with Restless Legs Syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Iron metabolism disorders; Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors Vifor
  • Most Recent Events

    • 23 Jun 2017 Primary endpoint of change in IRLS score from baseline to week 4 has not been met, according to results published in the Movement Disorders.
    • 23 Jun 2017 Results published in the Movement Disorders
    • 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top